Current Report Filing (8-k)
September 15 2022 - 8:38AM
Edgar (US Regulatory)
0001567892
false
0001567892
2022-09-14
2022-09-14
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C.
20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
the
Securities Exchange Act of 1934
Date of Report (Date
of earliest event reported): September 14, 2022
Mallinckrodt plc
(Exact name of registrant
as specified in its charter)
Ireland |
001-35803 |
98-1088325 |
(State or other jurisdiction of incorporation) |
(Commission File Number) |
(IRS Employer Identification No.) |
College Business & Technology Park, Cruiserath, Blanchardstown, Dublin 15, Ireland
(Address of principal executive offices)
+353 1 6960000
(Registrant’s
telephone number, including area code)
Check the appropriate
box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following
provisions:
| ¨ | Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| ¨ | Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ¨ | Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ¨ | Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
None
Indicate by check mark whether the registrant is an emerging growth
company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities
Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company ¨
If an emerging growth company, indicate by check mark if the registrant
has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant
to Section 13(a) of the Exchange Act. ¨
Item 7.01. |
Regulation FD Disclosure. |
On September 14, 2022, Mallinckrodt plc issued
a press release announcing that the U.S. Food and Drug Administration approved Terlivaz® (terlipressin) for injection.
A copy of the press release is being furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference
herein.
The information contained in this Item 7.01, including
Exhibit 99.1, shall be deemed to be “furnished” and shall not be deemed “filed” for purposes of Section 18
of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section,
nor shall such information be deemed incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange
Act.
Item 9.01. | Financial Statements and Exhibits. |
(d) Exhibits.
SIGNATURES
Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
|
|
MALLINCKRODT PLC |
|
|
(registrant) |
|
|
|
|
|
By: |
/s/ Mark Tyndall |
|
|
|
Mark Tyndall |
|
|
|
Executive Vice President, Chief Legal Officer & Corporate Secretary |
|
|
|
|
Date: September 14, 2022 |
|
|
|
Mallinckrodt () (USOTC:MNKKQ)
Historical Stock Chart
From Jun 2024 to Jul 2024
Mallinckrodt () (USOTC:MNKKQ)
Historical Stock Chart
From Jul 2023 to Jul 2024